We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$630M
1-Year Est. Return
108.65%
This Fund
S&P 500
This Quarter
Est. Return
+7.35%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$438M
AUM Growth
+$79M
(+22%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
37.75%
Top 10 Holdings %
Top 10 Hldgs %
55.67%
Holding
153
New
56
Increased
27
Reduced
23
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SMMF
Summit Financial Group, Inc.
SMMF
|
+$111M |
| 2 |
Novartis
NVS
|
+$41.1M |
| 3 |
RDHL
Redhill Biopharma
RDHL
|
+$23M |
| 4 |
Johnson & Johnson
JNJ
|
+$20M |
| 5 |
Eli Lilly
LLY
|
+$16.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$9.18M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$7.75M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$7.1M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$4.09M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
+$3.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.63% |
| 2 | Consumer Discretionary | 3% |
| 3 | Technology | 2.66% |
| 4 | Industrials | 1.84% |
| 5 | Consumer Staples | 1.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Curis
CRIS
$9.78M
| $1.24M | 0.28% |
+219
| New | +$1.32M |
|
77
Cytokinetics
CYTK
$10.5B
| $1.24M | 0.28% |
130,000
-37,000
| -22% | -$335K |
|
|
CDMO
78
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $1.22M | 0.28% |
+91,429
| New | +$1.2M |
|
79
Nektar Therapeutics
NKTR
$2.39B
| $1.21M | 0.28% |
+6,667
| New | +$1.32M |
|
80
Omeros
OMER
$857M
| $1.21M | 0.28% |
+100,000
| New | +$1.23M |
|
81
Xencor
XNCR
$1.5B
| $1.17M | 0.27% |
100,000
-48,000
| -32% | -$504K |
|
82
MacroGenics
MGNX
$235M
| $1.14M | 0.26% |
+41,000
| New | +$1.45M |
|
83
CALL
Gilead Sciences
GILD
$162B
| $1.14M | 0.26% |
+2,000
| New | +$157K |
|
|
QLTI
84
DELISTED
QLT Inc
QLTI
| $1.11M | 0.25% |
200,000
| – | – |
|
|
WINT
85
DELISTED
Windtree Therapeutics Inc
WINT
| $1.07M | 0.25% |
35,714
| – | – |
|
|
SRCL
86
DELISTED
Stericycle Inc
SRCL
| $1.07M | 0.24% |
9,439
-18,700
| -66% | -$2.16M |
|
87
Vanda Pharmaceuticals
VNDA
$307M
| $1.06M | 0.24% |
65,000
-30,000
| -32% | -$427K |
|
88
Tonix Pharmaceuticals
TNXP
$160M
| – | – |
0
| – | – |
|
89
Ellomay Capital Ltd
ELLO
$270M
| $995K | 0.23% |
100,853
+1,900
| +2% | +$18.8K |
|
|
KBIO
90
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
| $976K | 0.22% |
45,000
-3,125
| -6% | -$90.5K |
|
91
CALL
GSK
GSK
$104B
| $878K | 0.2% |
+2,400
| New | +$162K |
|
|
ALBO
92
DELISTED
Albireo Pharma Inc
ALBO
| $775K | 0.18% |
+9,463
| New | +$861K |
|
93
Compugen
CGEN
$222M
| $726K | 0.17% |
+69,109
| New | +$761K |
|
94
Ormat Technologies
ORA
$6B
| $704K | 0.16% |
+23,472
| New | +$632K |
|
95
PUT
iShares S&P 100 ETF
OEF
$20.1B
| $690K | 0.16% |
+3,000
| New | +$244K |
|
|
XLRN
96
DELISTED
Acceleron Pharma
XLRN
| $690K | 0.16% |
20,000
-30,000
| -60% | -$1.35M |
|
97
F5
FFIV
$22.9B
| $663K | 0.15% |
+6,222
| New | +$658K |
|
|
HSTO
98
DELISTED
Histogen Inc. Common Stock
HSTO
| $651K | 0.15% |
400
-38
| -9% | -$79.4K |
|
99
CALL
Vertex Pharmaceuticals
VRTX
$121B
| $543K | 0.12% |
+500
| New | +$39.6K |
|
|
IMGN
100
DELISTED
Immunogen Inc
IMGN
| $515K | 0.12% |
+34,500
| New | +$544K |
|
Similar funds
VIM
KCMH
FCFC
BI
PWW
TTSTC
SWP
EIM
Sphera Funds Management's Q1 2014 Portfolio in Review
As of Q1 2014, Sphera Funds Management held 153 positions worth $438M, up 22% from $359M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sphera Funds Management deployed $165M of net new capital in Q1 2014, opening 56 new positions and adding to 27 existing holdings. Its largest new stake was Summit Financial Group, Inc.: 10,921,656 shares worth $1.75M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $4.09M trimmed.
- Sphera Funds Management's largest Q1 2014 buy was Summit Financial Group, Inc.: 10,921,656 shares worth $1.75M.
- Sphera Funds Management added most to Novartis in Q1 2014, an estimated $41.1M increase.
- Sphera Funds Management's biggest Q1 2014 reduction was Teva Pharmaceuticals, cutting an estimated $4.09M.
- Sphera Funds Management fully exited Shire pic in Q1 2014, selling an estimated $9.18M.
- Sphera Funds Management's ten largest holdings make up 56% of its $438M portfolio in Q1 2014.
- Sphera Funds Management opened 56 new positions and closed 42 in Q1 2014.
- Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $438M.
Based on Sphera Funds Management's 13F filing for Q1 2014, filed 14 May 2014.